Islet amyloid polypeptide and insulin relationship in a longitudinal study of the genetically obese (ob/ob) mouse

Pancreas

Volumn 18, Issue 3, 1999, Pages 266-273

  Leckstrom A ^a   Lundquist, I ^b   Ma, Z ^a   Westermark, P ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Insulin; Islet amyloid polypeptide; Ob ob Mouse; Plasma Pancreas

Indexed keywords

AMYLOID PROTEIN; INSULIN; POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC SUSCEPTIBILITY; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; OBESITY; ORGAN SIZE; PANCREAS ISLET; PRIORITY JOURNAL;

EID: 0033022153     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199904000-00008     Document Type: Article

References (60)

1. Westermark P, Wernstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986;140:827-31.
2. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 1987;84:3881-5.
3. Westermark P, Wernstedt C, O'Brien TD, Hayden DW, Johnson KH. Islet amyloid in type 2 diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol 1987;127:414-7.
4. de Koning EJP, Bodkin JL, Hansen BC, Clark A. Diabetes mellitus in Macaca mulatta monkeys is characterized by islet amyloidosis and reduction in beta-cell population. Diabetologia 1993;36:378-84.
5. Cooper GJS, Willis AC, Clark A, Turner RC, Sim SB, Reid KBM. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987;84:8628-32.
6. Kahn SE, D'Alessio DD, Schwartz MW et al. Evidence of cose-cretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 1990;39:634-8.
7. Kanatsuka A, Makino H, Ohsawa H, et al. Secretion of islet amyloid polypeptide in response to glucose. FEBS Lett 1989;259:199-201.
8. Stridsberg M, Sandier S, Wilander E. Cosecretion of islet amyloid polypeptide (IAPP) and insulin from isolated rat pancreatic islets following stimulation or inhibition of b-cell function. Regul Peptides 1993;45:363-70.
9. Johnson KH, O'Brien TD, Betsholtz C, Westermark P. Islet amyloid: islet amyloid polypeptide, and diabetes mellitus. N Engl J Med 1989;321:513-8.
10. Groop LC, Eriksson JG. The etiology and pathogenesis of non-insulin-dependent diabetes. Ann Med 1992;24:483-9.
11. Luskey KL. Possible links between amylin and diabetes. Diabetes Care 1992;41:297-9.
12. Westermark P, Johnson KH, O'Brien TD, Betsholtz C. Islet amyloid polypeptide: a novel controversy in diabetes research. Diabetologia 1992;35:1-7.
13. Cooper GJS, Leighton B, Dimitriadis GD, et al. Amylin found in deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 1988;85:7763-6.
14. Hothersall JS, Muirhead RP, Wimalawansa S. The effect of amylin and calcitonin gene-related peptide on insulin-stimulated glucose transport in the diaphragm. Biochem Biophys Res Commun 1990; 169:451-4.
15. Zierath JR, Galuska D, Engström Å, et al. Human islet amyloid polypeptide at pharmacological levels inhibits insulin and phorbol ester-stimulated glucose transport in in vitro incubated human muscle strips. Diabetologia 1992;35:26-31.
16. Sowa R, Sanke T, Hirayama J et al. Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia 1990;33:118-20.
17. Ohsawa H, Kanatsuka A, Yamaguchi T, Makino H, Yoshida S. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 1989;160:961-7.
18. Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Macrae AD, Bloom SR. Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 1992;74:1032-5.
19. Lillioja S, Mott DM, Howard BV. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988;318:1217-25.
20. Eriksson J, Franssila-Kallunki A, Ekstrand A. et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989;321:337-43.
21. Groop LC, Saloranta C, Shank M, et al. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1991;72:96-107.
22. Enoki S, Mitsukawa T, Takemura J, et al. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1992; 15:97-102.
23. Hanabusa T, Kubo K, Oki C, et al. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1992;15:89-96.
24. Pieber TR, Stein DT, Ogawa A, et al. Amylin-insulin relationships in insulin resistance with and without diabetic hyperglycemia. Am J Physiol 1993;265:E446-53.
25. Mulder H, Ahrén B, Stridsberg M, Sundler F. Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Diabetologia 1995; 38:395-402.
26. Mulder H, Ahrén B, Sundler F. Islet amyloid polypeptide (amylin) and insulin are differently expressed in chronic diabetes induced by streptozotocin in rats. Diabetologia 1996;39:649-57.
27. Dubuc PU. The development of obesity, hyperinsulinemia and hyperglycemia in ob/ob mice. Metabolism 1976;26:1567-74.
28. Rerup C, Lundquist I. Blood glucose level in mice. Evaluation of a new technique of multiple serial sampling. Acta Endocrinol (Copenh) 1966;52:357-67.
29. Bruss ML, Black AL. Enzymatic microdetermination of glycogen. Anal Biochem 1978;84:309-12.
30. Christmanson L, Betsholtz C, Leckström A, et al. Islet amyloid polypeptide in the rabbit and European hare: studies on its relationship to amyloidogenesis. Diabetologia 1993;36:183-8.
31. Heding L. A simplified insulin radioimmunoassay method. In: Donato L, Milhaud G, Sirchis J, eds. Labelled proteins in tracer studies. Brussels: Euratom, 1966:345-50.
32. Leckström A, Östenson C-G, Efendiĉ S, et al. Increased storage and secretion of islet amyloid polypeptide relative to insulin in the spontaneously diabetic GK rat. Pancreas 1996;13:259-67.
33. Shafrir E. Development and consequences of insulin resistance: lessons from animals with hyperinsulinemia. Diabetes Metab (Paris) 1996;22:122-31.
34. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JAM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
35. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546-9.
36. Westman S. Development of the obese-hyperglycemic syndrome in mice. Diabetologia 1968;4:141-9.
37. Genuth SM. Hyperinsulinism in mice with genetically determined obesity. Endocrinology 1969;84:386-91.
38. Garthwaite TL, Martinson DR, Tseng LF, Hagen TC, Menahan LA. A longitudinal hormonal profile of the genetically obese mouse. Endocrinology 1980;107:671-6.
39. Findlay JA, Rookledge KA, Beloff-Chain A, Lever JD. A combined biochemical and histological study on the islets of Langerhans in the genetically obese hyperglycaemic mouse and in the lean mouse, including observations on the effects of streptozotocin treatment. J Endocrinol 1973;56:571-83.
40. Panagiotidis G, Lindström P, Stenström A, Lundquist I. Glucose modulation of islet monoamine oxidase activity in lean and obese hyperglycemic mice. Metabolism 1993;42:1398-404.
41. Ahrén B, Lundquist I. Modulation of basal insulin secretion in the obese, hyperglycemic mouse. Metabolism 1982;31:172-9.
42. Tassava TM, Okuda T, Romsos DR. Insulin secretion from ob/ob mouse pancreatic islets: effects of neurotransmitters. Am J Physiol 1992;262:E338-43.
43. Lundquist I. Lysosomal enzyme activities in pancreatic islets from normal and obese hyperglycemic mice. Metabolism 1985;34:1-9.
44. Lundquist I, Panagiotidis G, Salehi A. Islet acid glucan-1,4-α-glucosidase: a putative key enzyme in nutrient-stimulated insulin secretion. Endocrinology 1996;137:1219-25.
45. Dolais-Kitabgi J, Le Marchand-Brustel Y, Freychet P. Somatostatin in the pancreas and hypothalamus of obese mice. Diabetologia 1979;17:257-61.
46. Rizza RA, Mandarine LJ, Genest J, Baker BA, Gerich JE. Production of insulin resistance by hyperinsulinemia in man. Diabetologia 1985;28:70-5.
47. Cusin I, Terrataz J, Rohner-Jeanrenaud F, Jeanrenaud B. Metabolic consequences of hyperinsulinemia imposed on normal rats on glucose handling by white adipose tissue, muscles and liver. Biochem J 1990;267:99-103.
48. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. N Engl J Med 1993;329:1988-92.
49. Bailey CJ, Flatt PR. Islet defects and insulin resistance in models of obese non-insulin-dependent diabetes. Diabetes Metab Rev 1993;9:43S-50S.
50. Wardzala LJ, Hirschman M, Pofcher E, et al. Regulation of glucose utilization in adipose cells and muscle after long-term experimental hyperinsulinemia in rats. J Clin Invest 1985;76:460-9.
51. Laury MC, Penicaud L, Ktorza A, Benhaiem H, Bihoreau MT, Picon L. In vivo insulin secretion and action in the hyperglycemic rat. Am J Physiol 1989;257:E180-4.
52. Huang H-JS, Young AA, Koda JE, Tulp OL, Johnson MJ, Cooper GJS. Hyperamylinemia, hyperinsulinemia, and insulin resistance in genetically obese LA/N-cp rats. Hypertension 1992;19(suppl I):I-101-9.
53. Gill AM, Yen TT. Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice. Life Sci 1991;48:703-10.
54. Inoue K, Hiramatsu S, Hisatomi A, Umeda F, Nawata H. Hypersecretion of amylin from the perfused pancreas of genetically obese (fa/fa) rats and its alteration with aging. Metabolism 1993; 42:654-8.
55. Jamal H, Bretherton-Watt D, Suda K, Ghatei MA, Bloom SR. Islet amyloid polypeptide-like immunoreactivity (amylin) in rats treated with dexamethasone and streptozotocin. J Endocrinol 1990;126: 425-9.
56. Molina JM, Cooper GJS, Dimitriadis GD. Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes 1990;39:260-4.
57. Leighton B, Foot E. The effects of amylin on carbohydrate metabolism in skeletal muscle in vitro and in vivo. Biochem J 1990; 269:19-23.
58. Young AA, Wang MW, Cooper GJS. Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett 1991; 291:101-4.
59. Panagiotidis G, Salchi AA, Westermark P, Lundquist I. Homologous islet amyloid polypeptide: effects on plasma levels of glucagon, insulin and glucose in the mouse. Diabetes Res Clin Pract 1992;18:167-71.
60. Wagoner PK, Chen C, Worley JF, Dukes ID, Oxford GS. Amylin modulates β-cell glucose sensing via effects on stimulus-secretion coupling. Proc Natl Acad Sci USA 1993;90:9145-9.